Omega Funds
Venture capitalActively deployingBoston · Seed–Late Stage · 21 people tracked
Find your way into Omega Funds
1,703 people in our graph share verified history with the Omega Funds team — schools, employers, funds. One of them is your warm intro.
Investment thesis
Omega Funds invests in venture capital and growth equity opportunities across the life sciences sector.
Team · 21 people
from public directories
What they invest in
from 31 of 37 portfolio companiesBiotech ×27Healthtech ×12Medical Devices ×9Digital Health ×5Deep Tech ×4AI & Machine Learning ×2Advanced Manufacturing ×1Cybersecurity ×1
HQs:United States×27Switzerland×1Colombia×1
Investments · showing 25 of 37
founders shown can be your intro pathBy year:2026 · 32025 · 12024 · 42023 · 12022 · 12021 · 12020 · 12019 · 12018 · 12016 · 115 dated
Beta Bionics develops the iLet Bionic Pancreas System, an insulin delivery device for people with type 1 diabetes aged 6 and older that requires a physician's prescription.
Digital HealthHealthtechMedical DevicesIrvine, US
Edward Damiano(Executive Officer, Director)Sean Saint(President, Chief Executive Officer and Director)inStephen Feider(Chief Financial Officer)inMike Mensinger(Chief Product Officer)inSteven Russell(Chief Medical Officer)inMark Hopman(Chief Commercial Officer)in
Board seatFrancesco Draetta· per SEC Form D · $101.8M raise · filed Sep 2023
Co-investorsRTW Investments L.P.Soleus Capital
Biotechnology company developing orally available therapies for chronic inflammatory and autoimmune diseases.
BiotechNew York, US
Andreas Muehler(Executive Officer)inDaniel Vitt(Executive Officer, Director)inINDERPAL SINGH(Executive Officer)inHella Kohlhof(Executive Officer)Patrick Walsh(Executive Officer)Aron Stern(Executive Officer)
Board seatVincent Ossipow· per SEC Form D · $60M raise · filed Oct 2022
Co-investorsBayern Kapitalbmp VenturesFund+Pontifax Venture Capital
Nuvation Bio is a global oncology company that develops novel cancer therapies through its own drug discovery programs and business development, serving cancer patients.
BiotechHealthtechNew York, US
David Hung(Founder)inDavid Hung, M.D.(Executive Officer, Director)inDavid Hanley(Chief Technical Operations Officer)inGary Hattersley(Chief Scientific Officer)inStacy Markel(Chief People Officer)inPhilippe Sauvage(Chief Financial Officer)in
Board seatMichelle DoigClaudio Nessi· per SEC Form D · $275.3M raise · filed Oct 2020
Co-investorsAisling CapitalDecheng CapitalEcoR1 CapitalVertex Ventures China
X4 Pharmaceuticals is a biopharmaceutical company developing medicines for people living with rare immune disorders, including chronic neutropenia.
BiotechBoston, US
Mary DiBiase(Executive Officer)inChristophe Arbet-Engels(Executive Officer)inDavid Kirske(Executive Officer)inJohn Volpone(Executive Officer)inMark Baldry(Executive Officer)Adam Craig(Executive Officer, Director)in
Board seatClaudio Nessi· per SEC Form D · $50.5M raise · filed May 2017
Co-investorsBain Capital Life SciencesLumira VenturesNew Enterprise Associates (NEA)Partners ResoluteThynk CapitalPolaris Partners
Bicara Therapeutics is a clinical-stage biopharmaceutical company developing bifunctional antibody therapies that combine tumor-targeting with immune-modulating payloads to treat solid tumors.
Ivan Hyep(Chief Financial Officer and Treasurer)inLara Meisner(Chief Legal Officer, Compliance Officer and Corporate Secretary)inDavid Raben(Chief Medical Officer)in
Co-investorsAisling CapitalEight Roads VenturesF-Prime CapitalForesite CapitalPremji InvestRA Capital+5 more
Gossamer Bio is a clinical-stage biopharmaceutical company developing seralutinib, an investigational drug candidate for treating pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.
BiotechDigital HealthMedical DevicesSan Diego, US
Faheem Hasnain(Executive Officer, Director)inChristian Waage(Executive Officer)inSheila Gujrathi, MD(Founder)inBryan Giraudo(Executive Officer)Laura Carter, Ph.D.(Executive Officer)Robert Smith(Executive Officer)
Co-investorsARCH Venture PartnersBay City CapitalEcoR1 CapitalFoothill VenturesNew Enterprise Associates (NEA)Samsara BioCapital
Spruce Biosciences develops and commercializes therapies for serious neurological and endocrine disorders with unmet medical need, with a lead investigational enzyme replacement therapy (TA-ERT) for Mucopolysaccharidosis Type IIIB (Sanfilippo Syndrome Type B).
BiotechHealthtechSouth San Francisco, US
Javier Szwarcberg(Executive Officer, Director)inSamir Gharib(Executive Officer)inRICHARD KING(Executive Officer, Director)inJavier Szwarcberg, M.D., M.P.H.(Chief Executive Officer)
BoardSimpson Camilla(Director)Tiba Aynechi(Director)in
Co-investorsAisling CapitalHealthCapRiverVest Venture PartnersAbingworthNorwest Venture PartnersNovo Holdings+1 more
Trevi Therapeutics is a clinical-stage biopharmaceutical company developing Haduvio (oral nalbuphine ER), an investigational therapy for chronic cough that targets the central and peripheral cough reflex arc.
BiotechHealthtechNew Haven, US
Thomas Sciascia(Executive Officer)Jennifer Good(Co-Founder, President and CEO)inThomas Sciascia, M.D.(Co-Founder, Chief Scientific Officer)Lisa Delfini(Executive Officer)inWilliam Forbes(Executive Officer)inMichael Heffernan(Director)in
Co-investorsAPERTURE Venture PartnersFrazier Life SciencesNew Enterprise Associates (NEA)
Upstream Bio is a biotechnology company that sponsors clinical trials to develop products under investigation.
BiotechHealthtechWaltham, US
Rand Sutherland(Chief Executive Officer)inAllison Ambrose(General Counsel)inAaron Deykin(Chief Medical Officer & Head of R&D)inMike Gray(Chief Financial Officer and Chief Operating Officer)Adam Houghton(Chief Business Officer)inStacy Price(Chief Technology Officer)in
Co-investorsOrbiMedAccess IndustriesAccess BiotechnologyBain Capital Life SciencesDecheng CapitalSamsara BioCapital+2 more
Antares Therapeutics discovers and develops precision medicines, with a focus on small molecule therapies targeting previously undruggable oncology targets and other serious diseases.
AI & Machine LearningBiotechMedical DevicesCambridge, US
Adam Friedman(Chief Executive Officer)inAndrew Fedder(Executive Officer, Director)inBrian Piper(Executive Officer, Director)in
20260218151909.png)
Co-investorsAtlas VentureLightspeed Venture PartnersVida VenturesTenmileAbingworthBiotechnology Value Fund
Callio Therapeutics develops next-generation dual-payload antibody-drug conjugates (ADCs) with differentiated payload and linker technologies for targeted cancer treatment.
BiotechMedical DevicesSeattle, US
Piers Ingram(President, Co-Founder)inJerome Boyd-Kirkup(Chief Scientific Officer, Co-Founder)inZachary Hornby(Chief Executive Officer)
Co-investorsNovo HoldingsFrazier Life SciencesJeito CapitalNorwest Venture Partners
Alveus Therapeutics develops next-generation metabolic and obesity therapies, including its lead asset ALV-100 (in Phase 2) and a preclinical amylin pipeline of peptides, oral small molecules, and novel formats aimed at sustainable weight loss with better tolerability.
BiotechHealthtechLongevityPhiladelphia, US
Raj Kannan(Executive Officer, Director)
BoardIvan Gergel(Director)inJan Van de Bossche(Director)inGarrett Ingram(Director)Gregory Parekh(Director)
Board seatClaudio Nessi· per SEC Form D · $110.7M raise · filed Jan 2026
Co-investorsAndera PartnersAvego BioScience CapitalGlobal BioAccess FundJeito CapitalNew Rhein Healthcare Investors, LLCSeroba Life Sciences+2 more
BiotechBoston, US
Adam Friedman(Executive Officer, Director)inGary Glick(Executive Officer, Director)inAndrew Fedder(Executive Officer)inDarrin Stuart(Executive Officer)inErica Jackson(Executive Officer)inAmanda Valentino(Executive Officer)
Board seatOtello Stampacchia· per SEC Form D · $150M raise · filed Jul 2024
Co-investorsAtlas VentureAvoro Capital AdvisorsEcoR1 CapitalFrazier Life SciencesNextech InvestVida Ventures+3 more
Spiro Medical is a clinical-stage medical device company developing neuromodulation therapies for severe, uncontrolled asthma and other respiratory conditions.
BiotechHealthtechMedical DevicesBelleair Bluffs, US
Rinda Sama(Executive Officer)in
BoardBrian Mooney(Director)
Board seatClaudio Nessi· per SEC Form D · $69.1M raise · filed Jan 2026
Co-investorsAndera PartnersSupernova Invest
Third Arc Bio develops breakthrough treatments in oncology and immunology through advanced biologics engineering.
BiotechMedical DevicesLower Gwynedd, US
Joseph Erhardt(Executive Officer)inPeter Lebowitz(Executive Officer, Director)
BoardArjun Goyal(Director)in
Board seatFrancesco DraettaOtello Stampacchia· per SEC Form D
Co-investorsAndreessen HorowitzVida Venturesabrdn plcBiotechnology Value FundForesite CapitalHillhouse Investment+1 more
XII Medical develops neuromodulation therapies for treating obstructive sleep apnea, focusing on simplifying treatment options and improving patient outcomes.
Deep TechDigital HealthHealthtechMedical DevicesUnion City, US
Garrett Schwab(Chief Executive Officer)inShane Kreidel(Secretary and Chief Financial Officer)inZachary Eisen(Director)
BoardDuke Rohlen(Director)inJD Friedland(Director)
Board seatSaoussen Ben Halima· per SEC Form D
Co-investorsAPERTURE Venture PartnersBroadview VenturesCincyTechIntuitive VenturesJobsOhio VenturesAjax Health
GelSight develops high-resolution tactile imaging and surface metrology technology for measuring and analyzing surface properties in manufacturing.
Advanced ManufacturingAI & Machine LearningDeep TechHardwareWaltham, US
Micah K Johnson(Executive Officer, Director)Edward Adelson(Director)Janos Rohaly(Executive Officer)inWilliam J. Yost(Executive Officer, Director)
Co-investorsAnzu PartnersScout VenturesScout Ventures
nChroma Bio develops in vivo targeted delivery and genetic engineering technologies for genetic medicine applications.
BiotechDeep TechMedical Devices
Luke Gilbert, PhDKeith Joung, MD, PhDDavid Liu, PhDAngelo Lombardo, PhDLuigi Naldini, MD, PhDJonathan Weissman, PhD
Co-investorsAtlas VentureNewpath PartnersARCH Venture PartnersDCVC (Data Collective)F-Prime Capital5AM Ventures+1 more
Protego provides chargeback management software that automates dispute processes and tracks chargebacks in real time to help merchants identify patterns in fraudulent activity and recover revenue.
CybersecurityEnterprise SoftwareSaaSBogotá, CO
Pablo Rojas(Founder)in
Co-investorsNovartis Venture FundY CombinatorForbionGlilot Capital PartnersYK Bioventures
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Amunix Pharmaceuticals, Inc.Caldera Therapeutics, Inc.ESSA PharmaIkena Oncology, Inc.Morphic Holding, Inc.TheRas, Inc.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 9
9 IPOsBeta Bionics, IncNASDAQ: BBNXImmunicNASDAQ: IMUXNuvation BioNYSE: NUVBX4 PharmaNASDAQ: XFORBicara TherapeuticsNASDAQ: BCAXGossamer BioNASDAQ: GOSSSpruce BiosciencesNASDAQ: SPRBTrevi TherapeuticsNASDAQ: TRVIUpstream BioNASDAQ: UPB
Portfolio news
latest coverage across their companies
Nuvation Bio · aromatherapynaturals.com · Aug 22, 2026
Immunic · themarketsdaily.com · Aug 19, 2026
Bicara Therapeutics · fool.com · Aug 18, 2026
Spruce Biosciences · stocktitan.net · Aug 14, 2026
Alveus Therapeutics · fiercebiotech.com · Aug 12, 2026
Upstream Bio · stocktitan.net · Aug 11, 2026
Beta Bionics, Inc · tradingview.com · Aug 11, 2026
Trevi Therapeutics · investing.com · Aug 7, 2026
IPO stake values · per SEC filings · 5
Value of this firm's stake in each portfolio company at its IPO price, from the prospectus principal-stockholder table.
| Company | Owned | IPO price | At IPO | Stake value |
|---|---|---|---|---|
| Gossamer Bio | 11.0% | $16.00 | Feb 2019 | $111.3M |
| Bicara Therapeutics | 4.0% | $18.00 | Sep 2024 | $37.2M |
| Upstream Bio | 4.0% | $17.00 | Oct 2024 | $34.6M |
| Spruce Biosciences | 8.6% | $15.00 | Oct 2020 | $28.7M |
| Trevi Therapeutics | 4.4% | $10.00 | May 2019 | $7.8M |
Source: SEC S-1 / 424B prospectus filings. Stake value = shares beneficially owned × the initial public offering price, as disclosed — a market value at IPO, not a return multiple (the firm's original cost is not disclosed).
Frequently asked questions
- How many investments has Omega Funds made?
- Omega Funds has 37 tracked investments, 9 of which have exited, including 6 dated in the last 24 months.
- What stage does Omega Funds invest at?
- Omega Funds invests at the Seed, Series A, Series B, Series C, Late Stage stages.
- What sectors does Omega Funds focus on?
- Omega Funds focuses on Biotech, Medical Devices.
- Where is Omega Funds located?
- Omega Funds is headquartered in Boston, US.
Media · Podcasts & interviews
featuring the team#OptimumTV meets Omega Funds Otello Stampacchia to discuss the #lifescience investor outlook on 2026
Optimum Strategic Communications · Otello Stampacchia
Extrait Conférences BIOTECH MEDTECH HEALTHTECH LeZoom19H : Vincent Ossipow, Partner chez Omega Funds
Biotech Finances · Vincent Ossipow
Co-investors · 21
Atlas Venture is a life sciences venture capital firm with three decades of experience investing in and building biotech and medical innovation companies, including startups launched from its own incubator.
New Enterprise Associates (NEA) is a venture capital firm that invests in and provides long-term support to founders building new companies.
OrbiMed is a global healthcare-focused investment firm providing financing and operational support to companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.
Vida Ventures is a life sciences venture capital firm focused on transforming biomedical innovations into therapies that improve patients' lives.
Norwest Venture Partners is an investment firm whose growth equity team backs private, profitable, fast-growing companies, providing capital and hands-on support through its 'invited guest' approach.
F-Prime Capital is an early-stage-focused investment firm backing companies across life sciences, technology, healthtech and services, and crypto.
RA Capital is a multi-stage investment firm focused on healthcare, life sciences, and planetary health, investing across public and private markets and creating new companies through its Raven incubation platform.
venBio is a life sciences venture capital firm that partners with industry leaders to develop novel therapeutics and technologies addressing unmet medical needs.
The Novartis Venture Fund invests in innovative life science companies, focusing on biotechnology and biopharmaceuticals at various stages of growth, aiming to drive patient benefit and generate returns.
Agent Capital is a healthcare venture capital firm that invests in novel, differentiated therapeutics and treatments addressing unmet patient needs across all stages of development.
Avoro Capital Advisors is an investment firm focused on healthcare and life sciences, pursuing scientific breakthroughs that address unmet medical needs.
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
▶9 more co-investors
Canaan PartnersOUP (Osage University Partners)The Column GroupPfizer Venture InvestmentsSV Health InvestorsFrazier Healthcare PartnersHatteras Venture PartnersRoche Venture FundCofounders Capital
Firms observed investing alongside Omega Funds, from public investor directories. Shared companies are the overlap with Omega Funds's recorded portfolio.
Similar investors
Capricorn Partners is a Belgium-based, partner-owned independent management company for alternative investment funds, investing in innovative companies across digital, health and clean technologies with an ESG focus.
Korea Investment Partners is a South Korea-based venture capital firm that invests across multiple stages from early-stage startups through growth and buyout transactions, including venture debt and mezzanine financing. The firm operates across venture capital, middle market, and growth equity investment categories.
HM Venture Partners is a healthcare venture capital firm backing high-growth biotech and medtech companies worldwide across all stages, with three funds under management.
Panacea Venture is a global investment firm, spun out from Kleiner Perkins, focused on life sciences and healthcare innovation. It invests across geographies and stages, from company formation through expansion and public markets.